Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

1.60
+0.260019.40%
Post-market: 1.58-0.0180-1.13%19:58 EDT
Volume:4.68M
Turnover:7.27M
Market Cap:183.41M
PE:-1.07
High:1.68
Open:1.36
Low:1.36
Close:1.34
Loading ...

Fate Therapeutics Appoints Matthew Abernethy, M.b.a., to Its Board of Directors

THOMSON REUTERS
·
31 May

Press Release: Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Dow Jones
·
31 May

Fate Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Matt Abernethy

Reuters
·
31 May

Fate Therapeutics Is Maintained at Neutral by Baird

Dow Jones
·
14 May

Fate Therapeutics price target lowered to $4 from $5 at Baird

TIPRANKS
·
14 May

Fate Therapeutics, Inc. : Barclays Cuts Target Price to $2 From $10

THOMSON REUTERS
·
14 May

TD Cowen Remains a Hold on Fate Therapeutics (FATE)

TIPRANKS
·
14 May

Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Fate Therapeutics Q1 EPS $(0.32) Beats $(0.38) Estimate, Sales $1.63M Beat $1.14M Estimate

Benzinga
·
14 May

BRIEF-Fate Therapeutics Reports First Quarter 2025 Financial Results And Business Updates

Reuters
·
14 May

Fate Therapeutics Reports Q1 2025 Revenue of $1.6M, Operating Loss Amid $42.9M Expenses

Reuters
·
14 May

Fate Therapeutics Inc - Has $273 Mln Cash Runway Through 1H27

THOMSON REUTERS
·
14 May

Fate Therapeutics: Expanding FT819 Phase 1 Study to Include Treatment of Multiple Additional B Cell-Mediated Autoimmune Diseases and Ex-US Territories

THOMSON REUTERS
·
14 May

Fate Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
06 May

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
03 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
30 Apr

Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year

Simply Wall St.
·
27 Apr

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Zacks
·
15 Apr

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
14 Apr

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

GlobeNewswire
·
14 Apr